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ttp://dx.doi.org/10.1016/j.ajpath.2013.02.040Altered genome methylation is a hallmark of human malignancies. In this study, high-throughput
analyses of concordant gene methylation and expression events were performed for 91 human prostate
specimens, including prostate tumor (T), matched normal adjacent to tumor (AT), and organ donor
(OD). Methylated DNA in genomic DNA was immunoprecipitated with anti-methylcytidine antibodies
and detected by Affymetrix human whole genome SNP 6.0 chips. Among the methylated CpG islands,
11,481 islands were found located in the promoter and exon 1 regions of 9295 genes. Genes (7641)
were methylated frequently across OD, AT, and T samples, whereas 239 genes were differentially
methylated in only T and 785 genes in both AT and T but not OD. Genes with promoter methylation and
concordantly suppressed expression were identiﬁed. Pathway analysis suggested that many of the
methylated genes in T and AT are involved in cell growth and mitogenesis. Classiﬁcation analysis of the
differentially methylated genes in T or OD produced a speciﬁcity of 89.4% and a sensitivity of 85.7%.
The T and AT groups, however, were only slightly separated by the prediction analysis, indicating
a strong ﬁeld effect. A gene methylation prediction model was shown to predict prostate cancer relapse
with sensitivity of 80.0% and speciﬁcity of 85.0%. These results suggest methylation patterns useful in
predicting clinical outcomes of prostate cancer. (Am J Pathol 2013, 182: 2028e2036; http://
dx.doi.org/10.1016/j.ajpath.2013.02.040)Supported by the National Cancer Institute (grant RO1 CA098249 to
J.-H.L.), the American Cancer Society (grant RSG-08-137-01-CNE to
Y.P.Y.), and the University of Pittsburgh Cancer Institute.
J.-H.L., G.T., and Y.P.Y contributed equally to this work.Prostate cancer is one of the most prevalent malignancies
among American men, with approximately 280,000 new
cases diagnosed annually. Each year up to 28,050 patients
with prostate cancer die in the United States alone, and
mortality from prostate cancer is only second to lung carci-
noma in the United States.1 Although most prostate cancers
are indolent and responsive to the available hormone thera-
pies, a signiﬁcant number of cases become hormone refrac-
tory and metastatic. The precise cause of prostate cancer
progression has remained elusive, despite extensive research
efforts and recent advances in our understanding of this
disease. Comprehensive gene expression and genome anal-
yses have suggested that a global pattern of gene expression
and copy number alterations exist for prostate cancer.2e4 The
related gene products include critical molecules in signaling
pathways, DNA replication, cell growth, cell cycle check-
points, and apoptosis.5e8
Hypermethylation of the gene promoter is a well-known
epigenetic event that silences gene expression and is a criticalstigative Pathology.
.regulatory component in normal physiology, mediating gene
imprinting for inactivation of the X chromosome9 and tissue-
speciﬁc gene expression,10 and in pathological processes,
mediating inactivation of tumor suppressor genes and
promoting tumorigenesis.11,12 Addition of a methyl group to
the cytosine residue of CpG dinucleotides by methyltrans-
ferase creates a binding motif for methyl-cytosine binding
proteins, methyl-CpG-binding domain (MBD) or methyl-
CpG-binding protein 2 (MeCP2), which in turn produces
steric hindrance at the CpG clusters located in the promoter
regions to transcriptional activators or repressors.13,14
Silencing of genes involved in cell cycle control, cell
survival, DNA damage repair, and signal transduction is the
characteristics of cancer cells.15e23 There is a lack of global
Prostate Cancer Methylation Proﬁlingcorrelation of CpG island methylation and gene expression in
prostate cancer. To map the epigenetic regulation leading to
altered expression of hundreds of genes in prostate cancer, we
performed a genome-wide concordance analysis of gene
methylation and expression in matched prostate tumor (T),
benign prostate tissues adjacent to cancer (AT), and organ
donor prostate without history of urological disease or any
malignancy (OD). We found unique methylation proﬁles that
distinguished the T, AT, and OD samples.
Materials and Methods
Genomic DNA Preparation
Ninety-one specimens of prostate cancer and adjacent benign
prostate tissues and organ donor prostates were obtained from
University of Pittsburgh Tissue Bank in compliance with
institutional regulatory guidelines (Supplemental Table S1).
To ensure high purity (80%) of tumor cells, needle-
microdissection was performed by pathologists to isolate
the tumor cells from adjacent normal tissues (3-mmdistance
from the tumor). For AT and OD samples, similar needle-
microdissections were performed to achieve 80% epithelial
purity. GenomicDNAof these T andAT tissueswas extracted
with a commercially available tissue and blood DNA
extraction kit (Qiagen, Hilden, Germany). The protocols of
tissue procurement and procedure were approved by Institu-
tion Board of Review of the University of Pittsburgh.
Immunoprecipitation and Ampliﬁcation of Methylated
DNA
Each DNA sample was divided into two aliquots of 250 ng
and was digested with either StyI or Nsp1 (New England
BioLabs, Ipswich, MA) at 37C for 2 hours, followed by
ligation to the corresponding StyI or Nsp1 adapters (Affy-
metrix, Santa Clara, CA) at 16C for 16 hours. The two
adapter-ligated DNAs were pooled and puriﬁed with an
Amicon Ultra-centrifugation ﬁlter (Millipore, Billerica, MA).
Fifty nanograms of the puriﬁedDNA in 450mLof Tris-EDTA
buffer were denatured by boiling in water for 10 minutes.
Methylated DNA was then immunoprecipitated with 5 mg of
antie5-methylcytosine antibody (Zymo Research, Irvine,
CA) in immunoprecipitation buffer (10 mmol/L NaPO4, 140
mmol/L NaCl, and 0.05% Triton X-100, pH 7) by rocking at
4C for 2 hours. The immunocomplexes were captured with
magnetic bead-protein A/G (Millipore) by shaking at room
temperature for 30 minutes. Three washes were performed
with 1 mL of immunoprecipitation buffer, and additional
washes with 300 mL of elution buffer heated to 50C for
10 minutes were performed until the DNA in ﬂow-through
reached zero. Methylated DNA was then eluted from the
beads with 100 mL of elution buffer heated to 75C for
5 minutes. The eluted DNAwas PCR ampliﬁed with titanium
DNA polymerase and primer 002 from Affymetrix SNP 6.0
reagent kit, using 30 thermal cycles of 94C for 30 seconds,The American Journal of Pathology - ajp.amjpathol.org60C for 45 seconds, and 65C for 60 seconds. Ampliﬁcation
efﬁciency was assessed by resolving amplicons with 1%
agarose gel electrophoresis. Samples were then puriﬁed and
fragmented by incubating with DNase1 at 37C for
35 minutes. The fragmented DNA samples (range, 100e200
bp) were biotin labeled with terminal transferase at 37C for
4 hours and hybridized to Affymetrix human whole genome
SNP 6.0 chips at 50C for 19 hours. After washes with 6
SSPE (saline, sodium phosphate, EDTA) buffer and staining
with phycoerythrin streptoavidin in an automated Affymetrix
ﬂuid station, the chips were scanned byAffymetrix GeneChip
scanner 3000 7G.
Sample Baseline Genome Copy Number Analysis
To determine the baseline copy number of each sample,
genome DNA of each sample was analyzed with the Affyme-
trix SNP 6.0 chip. Brieﬂy, the adaptor ligated DNA was
prepared from StyI and Nsp1 digestion as described in Immu-
noprecipitation and Ampliﬁcation of Methylated DNA. The
efﬁciency of ampliﬁcationwas veriﬁed by resolving amplicons
with 1% agarose gel electrophoresis. The total amount of
puriﬁed amplicons was in the range of 200 to 250 mg.3,24 As
described in the section above, the amplicons were DNAse1
fragmented, biotin labeled, hybridized to the Affymetrix SNP
6.0 chips, and processed for genome copy number analysis.
DNA Methylation Analysis
The hybridization signals of methylation-enriched DNA from
91 prostate tissues were analyzed by Partek Genomics Suite
6.6 (Partek, Inc., St. Louis, MO). Pair-wise copy number
analyses of methylation-enriched DNA were performed with
genome copy numbers of the unenriched DNA samples as
baselines with criteria of marker numbers >10 and segment
length >2000 bp. The segments that were detected as ampli-
ﬁed or unchanged in comparison with the baseline copy
number of the duplicate samples were considered to be
enriched by the methylation-speciﬁc antibodies. These meth-
ylated fragments were then screened for CpG islands. Criteria
of 50% C and G and expected CpG of 0.65 in a region of
>200 bp was used to deﬁne a CpG island.25e27 The CpG
islands located in the region of 1000 bp upstream and 500 bp
downstream of mRNA start site of a gene were designated as
gene-associated CpG islands and were annotated through the
UCSC (University of California Santa Cruz) genome build
hg18. Microarray data location of Raw *.cel ﬁles of data will
be available at Gene Expression Omnibus (http://www.ncbi.
nlm.nih.gov/geo; accession number GSE45000).
Functional Analysis of Differentially Methylated Genes
The differential proﬁles of methylated genes were deter-
mined by comparing the CpG islands of T/OD, AT/OD, and
T/AT, respectively. For each given gene-associated CpG
island, the fraction of samples that were methylated was2029
Luo et altabulated for each group. A two-by-two contingency table
was constructed and Fisher exact test was performed to detect
the differential methylation of CpG islands. To examine
whether the differential methylations of these gene-associated
CpG islands were functional, the previously published U95
Affymetrix chip gene expression data of 130 cases of prostate
cancer and donors (overlapping 75 of 91 samples of our
present methylation analyses or 82%) were assessed.4 The
expression of each methylated gene was measured by
calculating Pearson correlation coefﬁcient between gene
expression values4,7 and methylation state vector (0,1) for
each matched sample (33). The differential gene expression
analysis that used a one-sided t-test was performed. A func-
tional methylated gene was deﬁned as a gene that was
detected as hypermethylated in the analysis and was shown to
have down-regulated gene expression. The difference in
methylation status of these functional methylated genes
between the compared groups was named as differential
functional methylation events in the analysis. Signiﬁcant
differences in methylation and expression were indicated by
a P value <0.05. Six sets of concordant genes were identi-
ﬁed, including the hypermethylated and hypomethylated gene
sets in T/D, AT/D, and T/AT groups.
Pathway Enrichment Analyses
Pathway analysis was performed for the six sets of concordant
genes.A total of 2287 pathwayswere curated fromMSigDB,28
which contains information from Biocarta, Kyoto Encyclo-
pedia of Genes and Genomes, Reactome, and Gene Ontology
databases. The one-sided Fisher exact test (overrepresentation)
was applied to calculate the statistical signiﬁcance of pathway
enrichment, and P values were corrected by the Benjamini-
Hochberg procedure for multiple comparisons to calculate
q values.
Statistical Prediction Model
Prediction (classiﬁcation) analyses were performed for the four
comparison groups: i) T versus OD, ii) AT versus OD, iii)
T relapse versus T nonrelapse, and iv) T fast relapse versus slow
relapse or nonrelapse. The conventional leave-one-out cross
validation (LOOCV) approach was used to assess accuracy.29
In LOOCV, one sample was left out for evaluation, and the
remaining samples were used to construct a prediction model,
which was then applied to the left-out sample evaluation for
accuracy of prediction. The process was repeated until all of the
samples were left out as test samples and the sensitivity and the
speciﬁcity of the model for prediction of cancer or normal were
achieved. The differentially methylated CpG islands were then
applied as predictive features in the prediction model, and the
top (parameter r) differentially methylated CpG islands (having
equal number of differentially hypermethylation and hypo-
methylation) were selected for their signiﬁcance in group
comparisons of hypermethylation and hypomethylation with
the use of Fisher exact test. To predict the left-out test sample,2030the percentage of concordance (parameter t) was calculated as
a threshold for themethylation pattern in the training setwith the
prediction model in the top (r) differentially hypermethylated
and hypomethylated CpG islands. Parameter (t) was used to
balance the sensitivity and speciﬁcity trade-off in the prediction
model. By varying p, a receiver operating characteristic (ROC)
curve for classiﬁcation was produced. In this analysis, the (r)
that produced the best area under the curve (AUC)was selected,
and the threshold pwas determined bymaximizing the Youden
index (sensitivityþ speciﬁcity 1) for the best sensitivity and
speciﬁcity trade-off andoverall accuracy rate.Thecriterionused
gave equal signiﬁcance in sensitivity and speciﬁcity. To eval-
uate whether the prediction result was better than that obtained
by a random approach, AUC was used as a test. Permutation
analyses were performed to assess the statistical signiﬁcance by
random shufﬂing of the class labels (case and control) with new
AUC values being calculated; this procedure was repeated
100 times to generate the null distribution. The P value was
calculated as thepercentage of 100nullAUCs frompermutation
and was greater than the observed AUC.
Methylation-Speciﬁc PCR
The genomic DNA from the same group of prostate tissue
samples was treated with sodium bisulﬁte (Epitec bisulﬁte kit;
Qiagen) at 95C for 5 minutes, followed by 60C for 4 hours,
and desulfonated as described in the manufacturer’s manual.
The bisulﬁte-converted DNA was ampliﬁed as previously
described,30,31 using CDKN1c methylation-speciﬁc primers
(50-CGCGGTCGTTAATTAGTCGC-30/50-ACACAACGCA-
CTTAACCTATAA-30) or CDKN1c unmethylation-speciﬁc
primers (50-TTTGTTTTGTGGTTGTTAATTAGTTGT-30/
50-ACACAACACACTTAACCTATAA-30) with the fol-
lowing thermal cycling conditions: 40 cycles of 95C for
30 seconds and 61C for 1 minute, followed by 72C for
2 minutes for methylation primers; or 40 cycles of 95C
for 30 seconds and 60C for 1 minute, followed by 72C for
2 minutes for unmethylation primers.
Results
To investigate the global DNA methylation patterns of
prostate cancer, methylated DNA segments from the prostate
genome were analyzed by detecting methylation-enriched
DNA with Affymetrix human whole genome SNP 6.0. The
methylated genome DNA samples were immunoprecipitated
by antibodies speciﬁc for 5-methylcytidine, ampliﬁed, and
hybridized to the SNP 6.0 chip. The methylation genome
DNA proﬁle of each sample was then analyzed with the
whole genome DNA proﬁle from the same sample as base-
line. Regions of DNA were deemed methylated if they were
detected as ampliﬁed or unchanged in comparison with the
matched whole genome proﬁle. A total of 34,413 genome
segments were identiﬁed as methylated regions. To study
whether all these genome segments were relevant to the
regulation of gene expression, we screened each for theajp.amjpathol.org - The American Journal of Pathology
Figure 1 Methylation of genomes of prostate cancer (T),
benign prostate tissue adjacent to cancer (AT), and organ
donor prostate (OD) samples. A: Methylation frequency of
CpG islands in 23 pairs of chromosomes of T, AT, and OD.
Gray columns represent fractions of samples that have
methylation in the corresponding CpG islands, whereas red
columns are the statistically signiﬁcant methylated CpG
islands (compared with the other two groups). B: Venn
diagram of methylated genes that occurred in at least 20%
of the samples.
Prostate Cancer Methylation Proﬁlingpresence of gene-associated CpG islands. CpG islands
located within 1000 bp upstream and 500 bp downstream of
the mRNA start site of a gene were considered potentially
functional and were included. Based on these criteria, 11,481
potentially functional CpG islands were identiﬁed along with
a total of 9136 genes. Among the gene-associated CpG
islands, 9082 were found to be methylated in T, 8458 in AT,
and 8093 in OD samples.
To investigate the differential methylation status of pros-
tate cancer-related CpG islands, the data were classiﬁed into
groups of T (nZ 47), AT (nZ 30), and OD (nZ 14) and
compared in pairs for each CpG island identiﬁed. The
proportion of each group’s samples that showed methylation
in each gene-associated CpG island assessed was determined,
and the distributions of these CpG islands in different chro-
mosomes are shown in Figure 1A. By comparing three group
pairs (T/OD þ AT, AT/T þ OD, and OD/T þ AT), the
differentially methylated CpG islands (P < 0.01) in T were
identiﬁed in comparison with OD or AT (Figure 1A). Simi-
larly, the genes associated with CpG islands that were differ-
entially methylated in AT or OD were identiﬁed (Figure 1A).
The number of genes that had at least one associated CpG
island and were found to be methylated in at least 20% of
samples in each patient group is shown in a Venn diagram
(Figure 1B). Many of these methylated segments were not
unique and overlapped with at least one of the other groups.
A total of 7641 genes were methylated in all three groupsThe American Journal of Pathology - ajp.amjpathol.org(T, AT, and OD). Genes (785) were methylated in the T and
AT groups but not in the OD group. Only 239 genes were
methylated in the T group only, compared with the 19 and 22
genes thatwere uniquelymethylated in theATandODgroups,
respectively. The differentially methylated genes between the
T andOD groupsmainly clustered in regions of chromosomes
1, 3, 15, and 17 (Figure 2). Interestingly, the T and AT groups
shared many of the same differentially methylated genes,
which were not methylated in the OD group. Few genes were
detected with differential methylation between the T group
and the AT group. To rule out the effect of age on methylation
pattern, samples from patients and organ donors of age 50
years were analyzed in an age-matched manner. The results
also suggested a signiﬁcant ﬁeld effect: 110 CpG islands were
found uniquely methylated in the T group, whereas only 27
were in the AT group and 25 in the OD group. Greater than
79% (423 of 533) of CpG islands differentially methylated in
T group (versus OD) were also methylated in AT samples.
Gene methylation generally has a negative effect on gene
expression. However, such effect can vary according to the
characteristic of an associated CpG island, the level or posi-
tion of the cytosine methylation, and other structural features.
To investigate whether methylation of gene-associated CpG
islands affected the corresponding gene expression, we per-
formed a concordance analysis on differentially methylated
genes with the use of gene expression data available from our
previously published Affymetrix U95 expression data set.2031
Figure 2 Ideograms of differential methyla-
tions between T, AT, and OD; T versus OD, AT
versus OD, and T versus AT. Upper panel: Differ-
ential methylation in T (blue) and OD (red). Middle
panel: Differential methylation in AT (blue) and
OD (red). Lower panel: Differential methylation in
T (blue) and AT (red).
Luo et alThese data overlapped 75 of 91 samples of the present
methylation analysis. Thus, the concordance analysis largely
reﬂected a direct methylation effect on expression. Differ-
entially methylated genes with down-regulation of gene
expression (P < 0.01) were designated as functional meth-
ylation. Genes with methylation but having no suppression of
gene expression were considered as nonfunctional methyla-
tion. Our analyses showed that 12.5% of the differentially
methylated genes are functional (Figure 3, AeC). The highest
frequency of functional differential methylation occurred in
the T group (n Z 47), with the lowest occurring in the OD
group (n Z 14) (Figure 3A). In particular, 95 of 650 genes
were functionally methylated in the T group, whereas only
7 of 35 were functionally methylated in the AT group. When
the AT group was compared with the OD group, 23 of 315
genes were classiﬁed as differentially methylated with sup-
pressed gene expression being detected in either theATorOD
group. Only ﬁve functional hypermethylation and one func-
tional hypomethylation events were found when the AT
group was compared with the T group. These results suggest
a signiﬁcant similarity between the T and AT groups in their
methylation patterns.
To understand the signiﬁcance of these differential DNA
methylation events, pathway analyses were performed on the
most signiﬁcantly differentially hypermethylated and hypo-
methylated genes of each group (as identiﬁed by the Fisher
exact test of independence, P < 0.01). The most frequently
identiﬁed pathways corresponding to the DNA methylation
and associated genes are shown in Supplemental Tables S2
and S3. Many of the hypermethylated genes in T (T/OD)
were involved in inhibition of cell proliferation or cell division,
such as cyclin-dependent kinase inhibitor 1C (CDKN1C) and
CDKN2D, whereas the hypomethylated genes in T were
involved in membrane transport. No signiﬁcant pathway
enrichment was identiﬁed when T was compared with AT. In
AT versus OD, an apoptosis pathway was suppressed in the
AT group [according to hypermethylation of some critical2032apoptotic genes, such as BCL2-associated X protein (BAX)
and proteasome (prosome, macropain) 26S unit, ATPase, 4
(PSMC4)], whereas the membrane transport molecules were
up-regulated by hypomethylation (Supplemental Table S3),
although with relatively weaker statistical signiﬁcance.
To investigatewhether the differentiallymethylated genes in
prostate samples are predictive of prostate cancer, we per-
formed classiﬁcation analyses with aggregated methylation
data for the differentially methylated CpG islands and the
prostate samples stratiﬁed as T, AT, or OD.We ﬁrst ranked the
differential methylation genes by P value. We then built and
optimized our classiﬁcation model by incremental inclusion of
top-ranked genes into the model, until the model showed no
improvement in prediction. With the use of 300 hyper-
methylated and 300 hypomethylated CpG islands identiﬁed in
the T group, our leave-one-out classiﬁcation of T versus OD
showed a prediction speciﬁcity of 89.4% and a sensitivity of
85.7% (Figure 4A). Interestingly, when this prediction model
was used to classify 30 of the AT samples, 80.0% (24 of 30) of
the AT samples were predicted as cancer. Only six AT samples
(20%) were predicted as normal, resembling a signiﬁcant ﬁeld
effect as reported for other studies.3 In the classiﬁcation of AT
versus OD, a model of 200 hypermethylated and 200 hypo-
methylated CpG islands was constructed, and the prediction
sensitivity of AT reached 71.4% and speciﬁcity reached 100%
(Figure 4B). As expected, the T versus AT classiﬁcation yiel-
ded no statistically signiﬁcant correct predictions.
Next, the LOOCVs were applied to predict the clinical
outcomes of prostate cancer samples. The cases of prostate
cancer were subdivided into groups of patients who relapsed
after radical prostatectomy and patients who had no relapse
for at least 5 years after the surgery. With the use of 20
differentially hypermethylated and 20 hypomethylated CpG
islands for the prostate cancer relapse samples, the prediction
speciﬁcity was 85.2% and sensitivity was 80.0% (Figure 5A)
for prostate cancer relapse. When the prostate cancer samples
were subdivided into fast relapsing [prostate-speciﬁc antigenajp.amjpathol.org - The American Journal of Pathology
Figure 3 Functional and differential methylation between T, AT, and OD. A: Differential methylation of CpG islands between T and OD. Left panel: CpG islands
differentially methylated in T samples (positive) versus OD (negative). Blue indicates CpG methylation associated with down-regulation of gene expression in
T samples. Right panel: CpG islands differentiallymethylated in OD samples (negative) versus T (positive). Green indicates CpGmethylation associated with down-
regulation of gene expression in OD samples. B: Differential methylation of CpG islands between T and AT. Left panel: CpG islands differentially methylated in
T samples (positive) versus AT (negative). Blue indicates CpG methylation associated with down-regulation of gene expression in T samples. Right panel: CpG
islands differentiallymethylated in AT samples (negative) versus T (positive). Green indicates CpGmethylation associatedwith down-regulation of gene expression
in AT samples. C: Differential methylation of CpG islands between AT and OD. Left panel: CpG islands differentially methylated in AT samples (positive) versus OD
(negative). Blue indicates CpG methylation associated with down-regulation of gene expression in AT samples. Right panel: CpG islands differentially methylated
in OD samples (negative) versus AT (positive). Green indicates CpG methylation associated with down-regulation of gene expression in OD samples.
Figure 4 Classiﬁcation of prostate samples based on differential
methylation. A: Classiﬁcation of T versus OD samples on the basis of 300
differentially methylated genes; ROC curve (left); methylation heat map
(pink indicates methylation and blue nonmethylation) (right). B: Classiﬁ-
cation of AT versus OD samples on the basis of 800 differentially methyl-
ated genes; ROC curve (left); methylation heat map (pink indicates
methylation and blue nonmethylation) (right).
Prostate Cancer Methylation Proﬁlingdoubling time (PSADT) of 4 months] and nonfast relapse
groups (nonrelapse or relapse with PSADT15 months), the
prediction speciﬁcity was 88.9% and sensitivity was 78.9%
for fast relapse, using as few as 20 hypermethylated and 20
hypomethylated CpG islands identiﬁed from fast relapse
tumors (Figure 5B).
To validate the ﬁndings of methylated DNA, the CDKN1C
gene was selected for methylation-speciﬁc PCR analysis. As
indicated in Figure 6, A and B, the ampliﬁed methylated
CDKN1c productswere detected inmost of the tumor samples,
and both methylated and unmethylated amplicons were
detected in the PC3 cell line and a number of tumor samples.
Discussion
Systematic analyses of gene methylation of prostate cancer
have been performed with various approaches, including
hybridization of sodium bisulﬁte-treated DNA to predesigned
oligo probe set32 or extension by predesigned primers,33 or
deep sequencing of methylated CpG-enriched DNA.34 These
high throughput analyses were performed with various
commercial or institutional speciﬁc platforms and revealed
various methylation patterns in prostate cancer.32,34,35 Anti-
methylcytosine antibody enrichment of methylated DNA had
been used to perform whole genome methylation analyses. It
had been successfully validated in several studies.36e39 WithThe American Journal of Pathology - ajp.amjpathol.orgthe use of a similar strategy, our genome methylation analysis
revealed distinct patterns of genome methylation in several
types of prostate tissues. No signiﬁcant preference was
observed toward high or low density of methylated CpG2033
Figure 5 Prediction of clinical outcomes of prostate samples on the basis
of differential methylation. A: Prediction of relapse versus no relapse for at
least 5 years from prostate cancer samples on the basis of 40 differentially
methylated genes; ROC curve (left); methylation heat map (pink indicates
methylation and blue nonmethylation) (right). B: Prediction of fast relapse
(PSADT <4 months) versus nonfast relapse from prostate cancer samples on
the basis of 40 differentially methylated genes; ROC curve (left); methylation
heat map (pink indicates methylation and blue nonmethylation) (right).
Figure 6 Methylation-speciﬁc PCR of CDKN1c CpG islands. A: Schematic
diagram of CpG islands in the promoter and exon 1 regions of CDKN1c. CpG
dinucleotides are indicated by the small red bar. The thick blue line represents
the span of the CpG island. U denotes primers designed for unmethylated
sequence, and M indicates methylated sequence. The mRNA start site is indi-
cated by an arrow. B: Methylation-speciﬁc PCR of prostate samples. The sufﬁx
T denotes prostate cancers, and the sufﬁx OD denotes organ donor prostates.
Luo et alislands on the basis of similar average CpG counts (nZ 15)
per 100 bp in a methylated CpG island detected in our assays
versus that (15.1) of all CpG islands in the human genome.
Epigenetic modiﬁcation of DNA, such as cytosine meth-
ylation in CpG dinucleotides, is one of the most important
regulatory mechanisms of gene expression. Promoter DNA
methylation, in particular, is critical for controlling genes
involved in cell cycle progression, cell survival, DNA
damage repair, and other signal transductions, and these
genes are often found to be silenced in clinical cancer
samples.15e23 However, information about gene methylation
in prostate cancer is still fragmented. No global functional
analyses have been performed to analyze whether gene
methylations have an effect on gene expressions. To our
knowledge, this is the ﬁrst report that systematically analyzes
the effects of CpG island methylations on gene expressions.
Our study suggests that the number of nonfunctional CpG
islands is much larger than previously thought.32,40
For many genes studied to date, methylation-induced gene
silencing has been attributed to the methylation of CpG
clusters in the promoter and exon 1 regions. Previous studies
of clinical samples of prostate cancer have shown that large
numbers of genes are down-regulated.4,41e43 However, our
methylation/expression concordance analyses showed that
only a small fraction (12.5%) of the methylated CpG islands
is functional, as evidenced by methylations accompanied by
down-regulated expression of the same genes. This analysis
suggests that not all CpG island methylations affect gene
expression. Additional factors, such as methylation density
or speciﬁc dinucleotide methylation, or the characteristics of
the CpG islands themselves may account for the different
effects on transcriptional activity. These functional CpG
islands may have signiﬁcant clinical implications. Unlike2034genome structural alterations, such as deletion or mutation,
DNA methylations are potentially reversible. Several epige-
netic treatments are currently available to reverse these
modiﬁcations and have been assessed for their potential to
treat cancers.43e46
Interestingly, the differentiallymethylated genes with down-
regulated expression in the T samples are enriched in signaling
pathways of cell cycle progression, mitogenic processes,
apoptosis, and membrane transporters. Concordant methyla-
tion/low expression events in two cyclin D-dependent kinase
inhibitors, CDKN1C and CDKN2D,47e49 occurred with fre-
quencies of 48.0% and 44.0%, respectively. These two genes
are known to block cell cycle entry fromG1 to S phase, thereby
inhibiting cell growth and proliferation. In addition, the cell
growth inhibitor with ring ﬁnger domain 1 (CGRRF1),50 which
acts as a p53 responsive protein in cell growth arrest, was
also methylated and down-regulated, suggesting a synergistic
action of these genes regulated by methylation in tumors.
Methylation-mediated silencing of theDNA-damage-inducible
transcript 3 (DDIT3)51,52 has been reported to suppress the
ability of cells to adequately respond to stresses. These per-
turbed functionsmay lead to genome instability in the tumor. In
addition, it is intriguing to ﬁnd that the differentiallymethylated
genes include a family of tumor suppressor genes, tissue
inhibitor ofmetalloproteinase 3 (TIMP1) to TIMP3. TIMP3 is a
protein suppressing metalloproteinase that degrades extracel-
lular matrix.53,54 TIMP1 gene promoter was previously found
methylated in prostate cancer, and the loss of TIMP1 protein
while gaining metalloproteinase has been attributed to the high
motility of tumor cells.54,55 Frequent methylation of TIMP1
(53%), TIMP2 (21%), and TIMP3 (6%) genes in prostate
cancer in our study suggests a concerted effect of inactivation of
inhibitors of metalloproteinase. This may enable cancer cells to
migrate and to invade into adjacent tissues. However, theajp.amjpathol.org - The American Journal of Pathology
Prostate Cancer Methylation Proﬁlingdiscovery of methylation of some of the mitogenic genes, such
as ﬁbroblast growth factor 9 (FGF9)56,57 andmitogen-activated
protein kinase 8 interacting protein 2 (MAPK8IP2), in prostate
cancer samples indicates a complicated pattern of cancer
methylation.
Previous studies suggest signiﬁcant ﬁeld effect of prostate
cancer through systematic genome methylation analy-
ses.32e34 The methylation patterns in T and AT in our anal-
yses were remarkably similar, although there were uniquely
methylated genes identiﬁed in T. Few genes were found to be
differentially methylated in the prostate cancer versus benign
tissues adjacent to prostate cancer. The differences between
organ donor prostate samples and benign prostate tissues
adjacent to cancer, however, were highly signiﬁcant, sug-
gesting that alterations of gene methylation precede the
morphologic malignancy. These ﬁndings suggest a strong
ﬁeld effect in prostate cancer, similar to that found in the
gene expression and genome analyses.3 The similarities
between these two groups (T and AT) suggest that epigenetic
alterations occurred much earlier than previously thought.
Finally, our classiﬁcation and prediction analyses with the
use of the differentially methylated genes in prostate cancer
yields an excellent prediction rate for tumor samples with
relapse (compared with nonrelapse samples) or for tumor
samples that have a short PSADT (compared with samples
having longer times). To our knowledge, this is the ﬁrst report
to suggest that a differential methylation proﬁle can be used
for prostate tumor prediction or prognostic evaluation with
highﬁdelity. Becausemethylationmodiﬁcation is a reversible
process, the prostate cancer-related hypermethylation and
hypomethylation genes identiﬁed in this study may represent
candidate targets for clinical therapeutic intervention.Acknowledgment
We thank Chia-Yueh Yen for her technical support.
J.-H.L., G.M., J.N., and Y.P.Y. conceived the idea.
J.-H.L. and Y.P.Y. directed and performed the experiments.
Y.P.Y., J.-H.L., and G.T. developed the strategy to analyze
the data. Y.D. and R.C. performed the statistical analyses.Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.ajpath.2013.02.040.References
1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA
Cancer J Clin 2012, 62:10e29
2. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C,
Thomas R, Dhir R, Finkelstein S, Michalopoulos G, Becich M,
Luo JH: Gene expression alterations in prostate cancer predicting
tumor aggression and preceding development of malignancy. J Clin
Oncol 2004, 22:2790e2799The American Journal of Pathology - ajp.amjpathol.org3. Yu YP, Song C, Tseng G, Ren BG, LaframboiseW,Michalopoulos G,
Nelson J, Luo JH: Genome abnormalities precede prostate cancer and
predict clinical relapse. Am J Pathol 2012, 180:2240e2248
4. Luo JH, Yu YP, Cieply K, Lin F, Deﬂavia P, Dhir R, Finkelstein S,
Michalopoulos G, Becich M: Gene expression analysis of prostate
cancers. Mol Carcinog 2002, 33:25e35
5. Magee JA,ArakiT,Patil S,EhrigT,TrueL,HumphreyPA,CatalonaWJ,
Watson MA, Milbrandt J: Expression proﬁling reveals hepsin over-
expression in prostate cancer. Cancer Res 2001, 61:5692e5696
6. Luo JH: Gene expression alterations in human prostate cancer. Drugs
Today (Barc) 2002, 38:713e719
7. Ernst T, Hergenhahn M, Kenzelmann M, Cohen CD, Ikinger U,
Kretzler M, Hollstein M, Grone HJ: [Gene expression proﬁling in
prostatic cancer]. German. Verh Dtsch Ges Pathol 2002, 86:165e175
8. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL:
Gene expression proﬁling predicts clinical outcome of prostate
cancer. J Clin Invest 2004, 113:913e923
9. Monk M, Grant M: Preferential X-chromosome inactivation, DNA
methylation and imprinting. Dev Suppl 1990, 55e62
10. Hu JF, Vu TH, Hoffman AR: Promoter-speciﬁc modulation of
insulin-like growth factor II genomic imprinting by inhibitors of DNA
methylation. J Biol Chem 1996, 271:18253e18262
11. YuG, TsengGC,YuYP,Gavel T,Nelson J,WellsA,MichalopoulosG,
Kokkinakis D, Luo JH: CSR1 suppresses tumor growth and metastasis
of prostate cancer. Am J Pathol 2006, 168:597e607
12. Yu YP, Yu G, Tseng G, Cieply K, Nelson J, Defrances M,
Zarnegar R, Michalopoulos G, Luo JH: Glutathione peroxidase 3,
deleted or methylated in prostate cancer, suppresses prostate cancer
growth and metastasis. Cancer Res 2007, 67:8043e8050
13. Lund AH, van Lohuizen M: Epigenetics and cancer. Genes Dev
2004, 18:2315e2335
14. Bird A: DNA methylation patterns and epigenetic memory. Genes
Dev 2002, 16:6e21
15. Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF,
Isaacs WB, Pitha PM, Davidson NE, Baylin SB: E-cadherin
expression is silenced by DNA hypermethylation in human breast and
prostate carcinomas. Cancer Res 1995, 55:5195e5199
16. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE,
Sidransky D, Baylin SB: Inactivation of the CDKN2/p16/MTS1 gene
is frequently associated with aberrant DNA methylation in all
common human cancers. Cancer Res 1995, 55:4525e4530
17. Kito H, Suzuki H, Ichikawa T, Sekita N, Kamiya N, Akakura K,
Igarashi T, Nakayama T, Watanabe M, Harigaya K, Ito H: Hyper-
methylation of the CD44 gene is associated with progression and
metastasis of human prostate cancer. Prostate 2001, 49:110e115
18. Vanaja DK, Cheville JC, Iturria SJ, Young CY: Transcriptional
silencing of zinc ﬁnger protein 185 identiﬁed by expression proﬁling is
associated with prostate cancer progression. Cancer Res 2003, 63:
3877e3882
19. Woodson K, Hayes R, Wideroff L, Villaruz L, Tangrea J: Hyper-
methylation of GSTP1, CD44, and E-cadherin genes in prostate
cancer among US Blacks and Whites. Prostate 2003, 55:199e205
20. Yoshiura K, Kanai Y, Ochiai A, ShimoyamaY, Sugimura T, Hirohashi S:
Silencing of the E-cadherin invasion-suppressor gene byCpGmethylation
in human carcinomas. Proc Natl Acad Sci U S A 1995, 92:7416e7419
21. Bastian PJ, Yegnasubramanian S, Palapattu GS, Rogers CG, Lin X,
De Marzo AM, Nelson WG: Molecular biomarker in prostate cancer:
the role of CpG island hypermethylation. Eur Urol 2004, 46:698e708
22. Nakayama M, Gonzalgo ML, Yegnasubramanian S, Lin X, De
Marzo AM, Nelson WG: GSTP1 CpG island hypermethylation as
a molecular biomarker for prostate cancer. J Cell Biochem 2004, 91:
540e552
23. Kang GH, Lee S, Lee HJ, Hwang KS: Aberrant CpG island hyper-
methylation of multiple genes in prostate cancer and prostatic intra-
epithelial neoplasia. J Pathol 2004, 202:233e240
24. Nalesnik MA, Tseng G, Ding Y, Xiang GS, Zheng ZL, Yu Y,
Marsh JW, Michalopoulos GK, Luo JH: Gene deletions and2035
Luo et alampliﬁcations in human hepatocellular carcinomas: correlation with
hepatocyte growth regulation. Am J Pathol 2012, 180:1495e1508
25. Jones PA, Takai D: The role of DNA methylation in mammalian
epigenetics. Science 2001, 293:1068e1070
26. Takai D, Jones PA: The CpG island searcher: a new WWW resource.
In Silico Biol 2003, 3:235e240
27. Takai D, Jones PA: Comprehensive analysis of CpG islands in human
chromosomes 21 and 22. ProcNatl Acad SciUSA 2002, 99:3740e3745
28. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL,
Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES,
Mesirov JP: Gene set enrichment analysis: a knowledge-based
approach for interpreting genome-wide expression proﬁles. Proc
Natl Acad Sci U S A 2005, 102:15545e15550
29. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M,
Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA,
Bloomﬁeld CD, Lander ES: Molecular classiﬁcation of cancer: class
discovery and class prediction by gene expression monitoring.
Science 1999, 286:531e537
30. Kobatake T, Yano M, Toyooka S, Tsukuda K, Dote H, Kikuchi T,
ToyotaM,OuchidaM,AoeM,DateH, PassHI, DoiharaH, ShimizuN:
Aberrant methylation of p57KIP2 gene in lung and breast cancers and
malignant mesotheliomas. Oncol Rep 2004, 12:1087e1092
31. Shin JY, Kim HS, Park J, Park JB, Lee JY: Mechanism for inacti-
vation of the KIP family cyclin-dependent kinase inhibitor genes in
gastric cancer cells. Cancer Res 2000, 60:262e265
32. Yu YP, Paranjpe S, Nelson J, Finkelstein S, Ren B, Kokkinakis D,
Michalopoulos G, Luo JH: High throughput screening of methylation
status of genes in prostate cancer using an oligonucleotide methyla-
tion array. Carcinogenesis 2005, 26:471e479
33. Kobayashi Y, Absher DM, Gulzar ZG, Young SR, McKenney JK,
Peehl DM, Brooks JD, Myers RM, Sherlock G: DNA methylation
proﬁling reveals novel biomarkers and important roles for DNA meth-
yltransferases in prostate cancer. Genome Res 2011, 21:1017e1027
34. Kim JH, Dhanasekaran SM, Prensner JR, Cao X, Robinson D,
Kalyana-Sundaram S, Huang C, Shankar S, Jing X, Iyer M, Hu M,
Sam L, Grasso C, Maher CA, Palanisamy N, Mehra R,
Kominsky HD, Siddiqui J, Yu J, Qin ZS, Chinnaiyan AM: Deep
sequencing reveals distinct patterns of DNA methylation in prostate
cancer. Genome Res 2011, 21:1028e1041
35. Kron K, Pethe V, Briollais L, Sadikovic B, Ozcelik H, Sunderji A,
Venkateswaran V, Pinthus J, Fleshner N, van der Kwast T, Bapat B:
Discovery of novel hypermethylated genes in prostate cancer using
genomic CpG island microarrays. PloS One 2009, 4:e4830
36. Kelkar A, Deobagkar D: A novel method to assess the full genome
methylation proﬁle usingmonoclonal antibody combinedwith the high
throughput based microarray approach. Epigenetics 2009, 4:415e420
37. Cerf A, Cipriany BR, Benitez JJ, Craighead HG: Single DNA
molecule patterning for high-throughput epigenetic mapping. Anal
Chem 2011, 83:8073e8077
38. Lisanti S, von Zglinicki T, Mathers JC: Standardization and quality
controls for the methylated DNA immunoprecipitation technique.
Epigenetics 2012, 7:615e625
39. Komashko VM, Acevedo LG, Squazzo SL, Iyengar SS,
Rabinovich A, O’Geen H, Green R, Farnham PJ: Using ChIP-chip
technology to reveal common principles of transcriptional repres-
sion in normal and cancer cells. Genome Res 2008, 18:521e532
40. Goering W, Kloth M, Schulz WA: DNA methylation changes in
prostate cancer. Methods Mol Biol 2012, 863:47e66
41. Tseng GC, Cheng C, Yu YP, Nelson J, Michalopoulos G, Luo JH:
Investigating multi-cancer biomarkers and their cross-predictability in
the expression proﬁles of multiple cancer types. Biomark Insights
2009, 4:57e79203642. LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V,
Gerald WL: Comprehensive gene expression analysis of prostate
cancer reveals distinct transcriptional programs associated with
metastatic disease. Cancer Res 2002, 62:4499e4506
43. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S,
Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM: Delineation of
prognostic biomarkers in prostate cancer. Nature 2001, 412:
822e826
44. Duan H, Zhang HJ, Yang JQ, Oberley LW, Futscher BW,
Domann FE: MnSOD up-regulates maspin tumor suppressor gene
expression in human breast and prostate cancer cells. Antioxid Redox
Signal 2003, 5:677e688
45. Nakayama T, Watanabe M, Yamanaka M, Hirokawa Y, Suzuki H,
Ito H, Yatani R, Shiraishi T: The role of epigenetic modiﬁcations in
retinoic acid receptor beta2 gene expression in human prostate
cancers. Lab Invest 2001, 81:1049e1057
46. Xiang N, Zhao R, Song G, Zhong W: Selenite reactivates silenced
genes by modifying DNA methylation and histones in prostate cancer
cells. Carcinogenesis 2008, 29:2175e2181
47. Riccio A, Cubellis MV: Gain of function in CDKN1C. Nat Genet
2012, 44:737e738
48. Giovannini C, Gramantieri L, Minguzzi M, Fornari F, Chieco P,
Grazi GL, Bolondi L: CDKN1C/P57 is regulated by the Notch target
gene Hes1 and induces senescence in human hepatocellular carci-
noma. Am J Pathol 2012, 181:413e422
49. Okuda T, Hirai H, Valentine VA, Shurtleff SA, Kidd VJ, Lahti JM,
Sherr CJ, Downing JR: Molecular cloning, expression pattern, and
chromosomal localization of human CDKN2D/INK4d, an inhibitor of
cyclin D-dependent kinases. Genomics 1995, 29:623e630
50. Madden SL, Galella EA, Riley D, Bertelsen AH, Beaudry GA:
Induction of cell growth regulatory genes by p53. Cancer Res 1996,
56:5384e5390
51. Pereira RC, Delany AM, Canalis E: CCAAT/enhancer binding
protein homologous protein (DDIT3) induces osteoblastic cell
differentiation. Endocrinology 2004, 145:1952e1960
52. Jauhiainen A, Thomsen C, Strombom L, Grundevik P, Andersson C,
Danielsson A, Andersson MK, Nerman O, Rorkvist L, Stahlberg A,
Aman P: Distinct cytoplasmic and nuclear functions of the stress
induced protein DDIT3/CHOP/GADD153. PloS One 2012, 7:e33208
53. Matthews FJ, Cook SD, Majid MA, Dick AD, Smith VA: Changes in
the balance of the tissue inhibitor of matrix metalloproteinases
(TIMPs)-1 and -3 may promote keratocyte apoptosis in keratoconus.
Exp Eye Res 2007, 84:1125e1134
54. Osman M, Tortorella M, Londei M, Quaratino S: Expression of
matrix metalloproteinases and tissue inhibitors of metalloproteinases
deﬁne the migratory characteristics of human monocyte-derived
dendritic cells. Immunology 2002, 105:73e82
55. Kenney MC, Chwa M, Atilano SR, Tran A, Carballo M,
Saghizadeh M, Vasiliou V, Adachi W, Brown DJ: Increased levels of
catalase and cathepsin V/L2 but decreased TIMP-1 in keratoconus
corneas: evidence that oxidative stress plays a role in this disorder.
Invest Ophthalmol Vis Sci 2005, 46:823e832
56. White AC, Xu J, Yin Y, Smith C, Schmid G, Ornitz DM: FGF9 and
SHH signaling coordinate lung growth and development through
regulation of distinct mesenchymal domains. Development 2006,
133:1507e1517
57. Iwata J, Tung L, Urata M, Hacia JG, Pelikan R, Suzuki A,
Ramenzoni L, Chaudhry O, Parada C, Sanchez-Lara PA, Chai Y:
Fibroblast growth factor 9 (FGF9)-pituitary homeobox 2 (PITX2)
pathway mediates transforming growth factor beta (TGFbeta)
signaling to regulate cell proliferation in palatal mesenchyme during
mouse palatogenesis. J Biol Chem 2012, 287:2353e2363ajp.amjpathol.org - The American Journal of Pathology
